Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px
Document › Details

Numab Therapeutics AG. (6/13/17). "Press Release: Numab and Kaken Pharmaceutical Co., Ltd. Enter into a Collaboration and Option Agreement". Pfäffikon.

Organisations Organisation Numab Therapeutics AG
  Group Numab (Group)
  Organisation 2 Kaken Pharmaceutical Co., Ltd. (TSE: 4521)
Products Product therapeutic antibody
  Product 2 anti-inflammatory drug
Index term Index term Kaken Pharmaceutical–Numab: therapeutic antibody, 201706– collab + license option €na for multispecific antibody for inflammatory disease
Persons Person Middendorp, Oliver (Numab 201703 CBO + Co-Founder before Esbatech 2004–2010)
  Person 2 Herklots, Hans (LifeSci 201805 LifeSci Advisors before Carpicorn One + TiGenix)
     


Numab Therapeutics AG (“Numab”) today announced a collaboration and option agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the identification of a multispecific antibody candidate for development in inflammatory disease.

Under the agreement, Kaken will obtain an option to conclude a license and codevelopment agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program. Further financial details are not disclosed.


About Numab

Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immuno-oncology and immunology, and has a number of discovery partnerships with pharmaceutical companies. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile. Numab is represented in Japan by PharmaBDL. For further information, visit www.numab.com.


About Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd. is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery. The Company concentrates its R&D resources in inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infection areas.


MEDIA CONTACTS
Numab Therapeutics AG
Oliver Middendorp
CBO & co-CEO
o.middendorp@numab.com

Capricorn One
Hans Herklots
capricorn1@bluewin.ch
+41 79 598 7149

   
Record changed: 2019-10-06

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Numab (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top